LLY

1,013.19

-0.14%↓

JNJ

201.41

-1.06%↓

ABBV

225.57

-1.64%↓

UNH

332.41

-0.46%↓

AZN

90.4

-0.14%↓

LLY

1,013.19

-0.14%↓

JNJ

201.41

-1.06%↓

ABBV

225.57

-1.64%↓

UNH

332.41

-0.46%↓

AZN

90.4

-0.14%↓

LLY

1,013.19

-0.14%↓

JNJ

201.41

-1.06%↓

ABBV

225.57

-1.64%↓

UNH

332.41

-0.46%↓

AZN

90.4

-0.14%↓

LLY

1,013.19

-0.14%↓

JNJ

201.41

-1.06%↓

ABBV

225.57

-1.64%↓

UNH

332.41

-0.46%↓

AZN

90.4

-0.14%↓

LLY

1,013.19

-0.14%↓

JNJ

201.41

-1.06%↓

ABBV

225.57

-1.64%↓

UNH

332.41

-0.46%↓

AZN

90.4

-0.14%↓

Начало・Списък с акции・Gossamer Bio Inc

Gossamer Bio Inc

Отворен

СекторЗдравеопазване

3.27 -3.82

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.2800000000000002

Максимум

3.42

Ключови измерители
By Trading Economics
Приходи	-9.9M -48M
Продажби	1.8M 13M
EPS	-0.21
Марж на печалбата	-362.728
Служители	144
EBITDA	-10M -45M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+215.79% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	180M 727M
Предишно отваряне	7.09
Предишно затваряне	3.27

Настроения в новините

By Acuity

50%

178 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

1.06 / 1.23 Подкрепа & съпротива

Gossamer Bio Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.12.2025 г., 20:41 ч. UTC

Печалби

Значими двигатели на пазара

America's Car-Mart Rises on Better-Than-Expected 2Q Revenue, $300 Million Term Loan

4.12.2025 г., 18:14 ч. UTC

Придобивния, сливания и поглъщания

Big Yellow Says It Will Terminate Takeover Talks With Blackstone

4.12.2025 г., 17:43 ч. UTC

Значими двигатели на пазара

Придобивния, сливания и поглъщания

Brera Holdings Signs Non-Binding Term Sheet to Acquire RockawayX

4.12.2025 г., 17:01 ч. UTC

Печалби

TD Bank Pushes Up Dividend After Underlying Earnings, Revenue Beat Expectations -- Update

4.12.2025 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Caution Over U.S. Labor Market, Japan Earnings -- Market Talk

4.12.2025 г., 23:45 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

4.12.2025 г., 21:54 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

4.12.2025 г., 21:54 ч. UTC

Пазарно говорене

Warehouse's Strategy to Lift Margins Easier Said Then Done -- Market Talk

4.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

4.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

4.12.2025 г., 21:48 ч. UTC

Пазарно говорене

Scales Hits Mark With Earnings Guidance -- Market Talk

4.12.2025 г., 21:37 ч. UTC

Печалби

Aerospace Start-Up Beta Posts Its First Earnings Report. The Stock Rises. -- Barrons.com

4.12.2025 г., 21:36 ч. UTC

Печалби

These Stocks Moved the Most Today: Meta Platforms, Salesforce, Snowflake, UiPath, Micron, Dollar General, Kroger, and More -- Barrons.com

4.12.2025 г., 20:15 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

4.12.2025 г., 20:15 ч. UTC

Пазарно говорене

Think Tank Calls For Bank of Canada Rate Hold Next Week -- Market Talk

4.12.2025 г., 20:04 ч. UTC

Пазарно говорене

Natural Gas Futures Extend Gains as U.S. Grows Cold -- Market Talk

4.12.2025 г., 19:54 ч. UTC

Пазарно говорене

Oil Futures Bolstered by Lasting Ukraine War, U.S. Macro Outlook -- Market Talk

4.12.2025 г., 19:44 ч. UTC

Придобивния, сливания и поглъщания

EQB CEO: PC Financial Deal Adds Scale to Compete With Larger Canadian Banks

4.12.2025 г., 19:44 ч. UTC

Придобивния, сливания и поглъщания

EQB CEO: PC Financial Tie-Up Brings Scale to Reach More Customers

4.12.2025 г., 19:44 ч. UTC

Придобивния, сливания и поглъщания

Equitable Bank Deal for PC Financial Adds Heft to Compete With Canada's Big Banks -- Interview

4.12.2025 г., 19:33 ч. UTC

Пазарно говорене

Gold Inches Higher as Traders Continue to Mull ADP Jobs Report -- Market Talk

4.12.2025 г., 19:01 ч. UTC

Придобивния, сливания и поглъщания

Paramount Raises Concerns About Netflix's Bid for Warner Bros. Discovery -- WSJ

4.12.2025 г., 19:01 ч. UTC

Придобивния, сливания и поглъщания

Paramount Wrote to Warner Bros. Discovery Again Wednesday -- WSJ

4.12.2025 г., 19:01 ч. UTC

Придобивния, сливания и поглъщания

Paramount Wrote Netflix Deal With Warner Bros. Would Likely 'Never Close,' Monday Letter Says -- WSJ

4.12.2025 г., 19:01 ч. UTC

Придобивния, сливания и поглъщания

Another Round of Bids for Warner Bros. Discovery Due Thursday, Sources Say -- WSJ

4.12.2025 г., 18:58 ч. UTC

Пазарно говорене

U.S.-Venezuela Military Tension Expected to Lift Oil Prices -- Market Talk

4.12.2025 г., 17:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

4.12.2025 г., 17:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

4.12.2025 г., 16:41 ч. UTC

Пазарно говорене

Gold Rises as Traders Await U.S. Inflation Data -- Market Talk

4.12.2025 г., 16:33 ч. UTC

Пазарно говорене

Печалби

Salesforce Customers Are Gaining Confidence in Agentforce -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Gossamer Bio Inc Прогноза

Ценова цел

By TipRanks

215.79% нагоре

12-месечна прогноза

Среден 10.8 USD 215.79%

Висок 15 USD

Нисък 8 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Gossamer Bio Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Gossamer Bio Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.06 / 1.23Подкрепа & съпротива

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Настроение

By Acuity

178 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.